MYND-778

MYND-778 is an investigational, orally administered psilocybin-based small-molecule drug candidate being developed by MYND Life Sciences for inflammatory and neuropsychiatric indications. It is described as an oral dosage form of psilocybin and related analogs, with the program focused on harnessing psilocybin’s anti‑inflammatory and immunomodulatory properties to blunt pathological inflammation, including in conditions such as sepsis and potentially other inflammation-driven disorders.[5][11] MYND’s related patent filings emphasize modulation of inflammatory pathways and inhibition of neuroinflammation via regulation of the human MYC oncogene, aiming to convert a pro‑inflammatory state into an anti‑inflammatory one across a range of neuropsychiatric diseases.[7][9] MYND-778 is in preclinical or early development, with no registered interventional clinical trials or approved indications identified to date.